Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 10:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 12,657 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Period A Clear all

Conditions: Kidney Failure
Interventions: Balcinrenone/dapagliflozin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Endometrial Neoplasms
Interventions: Time Restricted Eating (TRE) Schedule, Control Schedule; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older · Female only
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Seasonal Allergic Rhinitis
Interventions: PL nasal spray, fluticasone furoate (FF), PL eye drops, olopatadine (OLO); Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 45 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chronic Low-back Pain, Anxiety, Depression
Interventions: EaseVRx, Sham VR; Device
Lead sponsor: AppliedVR Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 1,093 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Van Nuys, California

Conditions: Synkinesis
Interventions: Neuromuscular Retraining Therapy (4 months), Chemodenervation (4 months), Neuromuscular Retraining + Chemodenervation; Other · Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 89 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Hydration
Interventions: Beverage. Incomplete block where each participant will complete 3 of the 6 possible glycerol-sodium blends in random order.; Other
Lead sponsor: PepsiCo Global R&D; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Valhalla, New York

Conditions: Fabry Disease
Interventions: A (migalastat), B (migalastat), C (migalastat), D (migalastat), E (migalastat); Drug
Lead sponsor: Amicus Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Polycystic Kidney, Autosomal Dominant
Interventions: Tolvaptan; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 11
States / cities: Denver, Colorado • Jacksonville, Florida • Atlanta, Georgia + 8 more

Conditions: Chronic Toxic Stress, Developmental/ Behavioral Regression in Young Children
Interventions: "traditional" Parents as Teachers (PAT), "hybrid" PAT model; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 14 Years to 21 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Healthy
Interventions: PF-07081532, Cyclosporine, Itraconazole; Drug · Device
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Cushings Disease
Interventions: Pasireotide with or without cabergoline; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 2
States / cities: Birmingham, Alabama • Portland, Oregon

Conditions: HIV/AIDS, Contraception
Interventions: tenofovir/emtricitabine, DMPA; Combination Product · Drug
Lead sponsor: Sharon Achilles; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Neurocognitive Dysfunction
Interventions: Xenon; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 20 Years to 40 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: K-877 CR Tablet A, K-877 CR Tablet B, K-877 CR Tablet E, K-877 IR Tablet; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Diabetes Mellitus
Interventions: Patient Activation, Provider Training, Quality Improvement, Community Outreach; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 6,209 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 6
States / cities: Chicago, Illinois

Conditions: Pulmonary Hypertension, Interstitial Lung Disease (ILD), Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Interventions: inhaled mosliciguat, Dry Powder Inhaler; Drug · Device
Lead sponsor: Pulmovant, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 13
States / cities: Santa Barbara, California • Torrance, California • Kissimmee, Florida + 10 more

Conditions: Ketosis
Interventions: Ketone Supplement, Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale, Blood Draw, Breath Reading, Heart Rate Variability, CGM/CKM, DXA, Urine Analysis; Dietary Supplement · Behavioral · Biological + 2 more
Lead sponsor: Ohio State University; Other
Eligibility: 20 Years to 30 Years · Male only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Critical Illness, Palliative Care, Older Adults, Informal Caregivers, Care Delivery Model
Interventions: ICUconnect, Usual care; Behavioral · Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 4
States / cities: Birmingham, Alabama • New York, New York • Durham, North Carolina + 1 more

Conditions: HIV Prevention
Interventions: TFV 1% vaginal gel, HEC Placebo Gel; Drug
Lead sponsor: CONRAD; Other
Eligibility: 15 Years to 17 Years · Female only
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 2
States / cities: The Bronx, New York • Salt Lake City, Utah

Conditions: Substance-Related Disorders
Interventions: Peer-Enhanced Motivational Interviewing, Waitlist Control; Behavioral · Other
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 18 Years to 29 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Heart Arrest
Interventions: Laerdal Q-CPR /technology; Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 1,586 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Seattle, Washington

Conditions: Macular Degeneration
Interventions: ranibizumab, verteporfin; Drug
Lead sponsor: Texas Retina Associates; Other
Eligibility: 50 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 3
States / cities: Santa Barbara, California • Ann Arbor, Michigan • Arlington, Texas

Conditions: Childhood Apraxia of Speech
Interventions: Dynamic Temporal and Tactile Cueing - Connect (DTTC-Connect); Behavioral
Lead sponsor: New York University; Other
Eligibility: 3 Years to 12 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Hempstead, New York • New York, New York

Conditions: Cystic Fibrosis
Interventions: Discontinuation of hypertonic saline (HS), Continuation of hypertonic saline (HS); Other
Lead sponsor: Nicole Hamblett; Other
Eligibility: 12 Years and older
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 81
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 69 more

Search by objective public record fields.

Study of the Effect of Haemodialysis on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone/Dapagliflozin

Time Restricted Eating (TRE) Among Native Hawaiian/Pacific Islander Women at Risk for Endometrial Cancer

Effect of Veramyst and Olopatadine 0.2% Opthalmic Solution on Allergy Symptoms

EaseVRx-8w+ for the Treatment of Chronic Lower Back Pain

Mixed Methods Investigation of Chronic Facial Paralysis in Individuals With Synkinesis

Effect of Glycerol-Electrolyte Beverages on Fluid Balance in Healthy Euhydrated Men and Women at Rest

Migalastat Food Effect Study

Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

(YMP) Young Moms Program

A Drug-Drug Interaction Study to Examine the Impact of Itraconazole and Cyclosporine on PF-07081532 Pharmacokinetics in Overweight or Obese Adults

Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease

Pharmacokinetics and Pharmacodynamics of DMPA With HIV PrEP

A Test of Neural Inertia in Humans With Xenon

Compare the Pharmacokinetic of K-877 Controlled Release (CR) and Immediate Release (IR) Tablets in Healthy Adults.

Improving Diabetes Care and Outcomes on the South Side of Chicago

A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

Strategies to Augment Ketosis: Optimization of Ketone Delivery Strategies

Improving Needs Among Older Adults

Safety and Acceptability of Tenofovir 1% Gel in Adolescent Females

Peer MI for Substance-using Emerging Adults

Automated Real-time Feedback on CPR Study

Ranibizumab and Reduced Fluence PDT for AMD

Motor-based Intervention for Childhood Apraxia of Speech: DTTC-Connect

Impact of Discontinuing Hypertonic Saline in People With CF on Highly Effective CFTR Modulators- A SIMPLIFY Sub-Study